Citizens JMP analyst Roy Buchanan raised the firm’s price target on Dynavax (DVAX) to $32 from $31 and keeps an Outperform rating on the shares. Dynavax continues to focus on priorities in HEPLISAV-B, business development, and the pipeline with the board battle behind it, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Dynavax’s Strong Q2 Performance and Strategic Growth Justify Buy Rating
- Dynavax Technologies Reports Strong Q2 2025 Results
- Dynavax: Strong Heplisav Sales and Promising Vaccine Pipeline Justify Buy Rating
- Dynavax reports Q2 EPS 14c vs. 8c last year
- Dynavax raises 2025 Heplisav-B net product revenue view to $315M-$325M